Yazar "Havrdova, E." için listeleme

Toplam kayıt 18, listelenen: 1-18

Anti-inflammatory disease modifying treatment does not attenuate disability progression in secondary progressive multiple sclerosis

Lorscheider, J.; Jokubaitis, V.; Spelman, T.; Izquierdo, G.; Lugaresi, A.; Havrdova, E.; Ramo-Tello, C. (Sage Publications Ltd, 2016)

…
Cladribine versus fingolimod, natalizumab and interferon beta for multiple sclerosis

Kalincik, T.; Jokubaitis, V.; Spelman, T.; Horakova, D.; Havrdova, E.; Trojano, M.; Barnett, M. (Sage Publications Ltd, 2017)

…
Clinical and therapeutic predictors of relapse and disability outcomes in neuromyelitis optica spectrum disorder

Kunchok, A.; Malpas, C.; Horakova, D.; Havrdova, E.; Alroughani, R.; Terzi, M.; Altintas, A. (Sage Publications Ltd, 2018)

…
Comparative analysis of MS outcomes in dimethyl fumarate-treated patients relative to propensity matched fingolimod, interferon, glatiramer acetate, or teriflunomide

Spelman, T.; Kalincik, T.; Trojano, M.; Grand'Maison, F.; Izquierdo, G.; Havrdova, E.; Butzkueven, H. (Sage Publications Ltd, 2016)

…
A comparative-effectiveness analysis applying a 3 way propensity matching to real-world data from MSBase Registry in preparation for a cost effectiveness model: patients switching within firstline agents or to natalizumab or fingolimod in active RRMS

Spelman, T.; Havrdova, E.; Horakova, D.; Trojano, M.; Lugaresi, A.; Izquierdo, G.; Butzkueven, H. (Sage Publications Ltd, 2017)

…
Comparison of efficacy and persistence of first line fingolimod vs interferon-beta/glatiramer in the presence of prior disease activity

Spelman, T.; Izquierdo, G.; Alroughani, R.; Fernandez Bolaos, R.; Havrdova, E.; Horaova, D.; Butzkueven, H. (Sage Publications Ltd, 2015)

…
Defining secondary progressive multiple sclerosis

Lorscheider, J.; Buzzard, K.; Jokubaitis, V.; Spelman, T.; Havrdova, E.; Horakova, D.; Van Pesch, V. (Sage Publications Ltd, 2015)

…
Determinants of disability accumulation in secondary-progressive multiple sclerosis.

Lizak, N.; Malpas, C.; Sharmin, S.; Havrdova, E.; Horakova, D.; Izquierdo, G.; Kalincik, T. (Sage Publications Ltd, 2018)

…
Disease modifying therapy improves disability outcomes in relapsing-remitting multiple sclerosis over 22 years

Kalincik, T.; Spelman, T.; Jokubaitis, V.; Horakova, D.; Havrdova, E.; Trojano, M.; Pucci, E. (Sage Publications Ltd, 2017)

…
The effect of disease-modifying treatments on conversion to secondary progressive multiple sclerosis

Brown, J. W. L.; Coles, A.; Horakova, D.; Havrdova, E.; Trojano, M.; Izquierdo, G.; McCombe, P. (Sage Publications Ltd, 2017)

…
Effectiveness of fingolimod, dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis: a comparative longitudinal study

Kalincik, T.; Spelman, T.; Jokubaitis, V.; Horakova, D.; Havrdova, E.; Izquierdo, G.; McCombe, P. (Sage Publications Ltd, 2017)

…
Evaluation of common criteria of progression of disability in a large observational cohort

Kalincik, T.; Jokubaitis, V.; Spelman, T.; Horakova, D.; Havrdova, E.; Trojano, M.; Terzi, M. (Sage Publications Ltd, 2014)

…
Immunomodulatory therapy slows accumulation of disability in moderately advanced multiple sclerosis

Lizak, N.; Lugaresi, A.; Alroughani, R.; Lechner-Scott, J.; Slee, M.; Havrdova, E.; Rio, M. E. (Sage Publications Ltd, 2015)

…
Individual response to disease modifying therapies: a global observational cohort study

Kalincik, T.; Sobisek, L.; Jokubaitis, V.; Spelman, T.; Horakova, D.; Havrdova, E.; Granella, F. (Sage Publications Ltd, 2016)

…
Pregnancy incidence and therapy exposure in relapsing forms of MS: a 12-year retrospective multicentre analysis

Jokubaitis, V. G.; Havrdova, E.; Horakova, D.; Izquierdo, G.; Kalincik, T.; van der Walt, A.; Pucci, E. (Sage Publications Ltd, 2017)

…
The risk of relapse following on-treatment clinically silent lesions in patients with relapsing-remitting multiple sclerosis

Brown, J. W. L.; Lugaresi, A.; Horakova, D.; Havrdova, E.; Jokubaitis, V.; Lechner-Scott, J.; Hutchinson, M. (Sage Publications Ltd, 2017)

…
Risk of secondary progressive multiple sclerosis: a longitudinal study [Meeting Abstract]

Fambiatos, A.; Jokubaitis, V.; Spelman, T.; Horakova, D.; Havrdova, E.; Trojano, M.; Granella, F. (Sage Publications Ltd, 2017)

…
Timing of high-efficacy disease modifying therapies for relapsing-remitting multiple sclerosis

Merkel, B.; Jokubaitis, V.; Spelman, T.; Horakova, D.; Havrdova, E.; Trojano, M.; Spitaleri, D. (Sage Publications Ltd, 2017)

…